How many stocks are there of Novacyt?
The current number of stocks of Novacyt is 70.63 M undefined.
Novacyt Stocks 2024
Novacyt Stocks
70.63 M
Ticker
ALNOV.PA
ISIN
FR0010397232
WKN
A12CFH
In 2024, Novacyt had 70.63 M outstanding stocks, a 0% change from the 70.63 M stocks in the previous year.
The Novacyt Stocks history
| YEAR | NUMBER OF STOCKS (undefined GBP) |
|---|---|
| 2025e | 70.63 |
| 2024e | 70.63 |
| 2023 | 70.63 |
| 2022 | 70.63 |
| 2021 | 70.63 |
| 2020 | 68.19 |
| 2019 | 45.73 |
| 2018 | 37.66 |
| 2017 | 23.08 |
| 2016 | 12.09 |
| 2015 | 6.79 |
| 2014 | 4.44 |
| 2013 | 2.93 |
| 2012 | 2.43 |
| 2011 | 0.15 |
| 2010 | 0.13 |
| 2009 | 0.13 |
| 2008 | 0.12 |
Novacyt shares outstanding FR0010397232 · A12CFH
The number of shares was Novacyt in 2023 — This indicates how many shares 70.626 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Novacyt earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Novacyt's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Novacyt’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Novacyt's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2008 | 120,000 Aktien |
| 2009 | 130,000 Aktien |
| 2010 | 130,000 Aktien |
| 2011 | 150,000 Aktien |
| 2012 | 2.43 M Aktien |
| 2013 | 2.93 M Aktien |
| 2014 | 4.44 M Aktien |
| 2015 | 6.79 M Aktien |
| 2016 | 12.09 M Aktien |
| 2017 | 23.08 M Aktien |
| 2018 | 37.66 M Aktien |
| 2019 | 45.73 M Aktien |
| 2020 | 68.19 M Aktien |
| 2021 | 70.63 M Aktien |
| 2022 | 70.63 M Aktien |
| 2023 | 70.63 M Aktien |
| 2024e | 70.63 M Aktien |
| 2025e | 70.63 M Aktien |
Novacyt Aktienanalyse
What does Novacyt do?
Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Novacyt's Shares Outstanding
Novacyt's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Novacyt’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Novacyt’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Novacyt’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Novacyt stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Novacyt are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Novacyt evolved in recent years?
The number of shares of Novacyt has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Novacyt as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Novacyt?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Novacyt pay?
Over the past 12 months, Novacyt paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novacyt is expected to pay a dividend of 0 GBP.
What is the dividend yield of Novacyt?
The current dividend yield of Novacyt is .
When does Novacyt pay dividends?
Novacyt pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novacyt?
Novacyt paid dividends every year for the past 0 years.
What is the dividend of Novacyt?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novacyt located?
Novacyt is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novacyt kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novacyt from 8/17/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/17/2024.
When did Novacyt pay the last dividend?
The last dividend was paid out on 8/17/2024.
What was the dividend of Novacyt in the year 2023?
In the year 2023, Novacyt distributed 0 GBP as dividends.
In which currency does Novacyt pay out the dividend?
The dividends of Novacyt are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novacyt
Our stock analysis for Novacyt Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
